ARUP's Laboratory Test Directory

BCR-ABL1 Kinase Domain Mutation Analysis : 0040138
[ image for: Time Sensitive]
Time Sensitive
[ image for: Additional Technical Information]
Additional Technical Information


Mnemonic: BCRABL MUT

Methodology: Polymerase Chain Reaction/Sequencing
Performed: Varies
Reported: 10-12 days
Specimen Required: Collect: Lavender (EDTA) or bone marrow (EDTA).

Specimen Preparation: Transport 5 mL whole blood or 3 mL bone marrow. (Min: 1 mL whole blood or 1 mL bone marrow)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.

Stability (collection to initiation of testing): Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable

Reference Interval:
By report
Interpretive Data: Refer to report

See Compliance Statement B: www.aruplab.com/CS
Note: Assay detects more than 90 percent of the mutations that may lead to imatinib resistance.
CPT Code(s): 81403, G0452
Cross References: ABL Mutation (BCR-ABL1 Kinase Domain Mutation Analysis) , ABL1 Mutation Analysis for Imatinib (BCR-ABL1 Kinase Domain Mutation Analysis) , BCR-ABL1 Mutation (BCR-ABL1 Kinase Domain Mutation Analysis) , Gleevec Resistance Mutation Analysis (BCR-ABL1 Kinase Domain Mutation Analysis) , Imatinib Mesylate Resistance Analysis (BCR-ABL1 Kinase Domain Mutation Analysis) , Imatinib Resistance Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)